Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
Optimi Health Corp., a NASDAQ-listed pharmaceutical company specializing in regulated psychedelic drug products, announced the successful first export of psilocybin biomass and finished capsules to the United Kingdom. This shipment supports a planned Phase 2 clinical trial, marking Optimi's entry into the UK clinical research market. The products w…